Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes
- PMID: 23782387
- PMCID: PMC3967885
- DOI: 10.1111/hpb.12135
Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes
Abstract
Objectives: This study was conducted to determine the incidence of early stasis in radioembolization using resin yttrium-90 (Y-90) microspheres, to evaluate potential contributing factors, and to review initial imaging outcomes.
Methods: Patients in whom early stasis occurred were compared with those in whom complete delivery was achieved for tumour type and vascularity, tumour : normal liver ratio (T : N ratio) at technetium-99m-macroaggregated albumin (Tc-99m-MAA) angiography, previous intra-arterial therapy, and infusion site (left, right or whole liver). Tumour response was evaluated at 3 months and defined according to whether a partial response and stable disease versus progressive disease were demonstrated.
Results: A total of 71 patients underwent 128 Y-90 infusions in which 26 (20.3%) stasis events occurred. Hypervascular and hypovascular tumours had similar rates of stasis (17.4% versus 27.8%; P = NS). The mean ± standard deviation T : N ratio was 3.03 ± 1.54 and 3.66 ± 2.79 in patients with and without stasis, respectively (P = NS). Stasis occurred in 14 of 81 (17.3%) and 12 of 47 (25.5%) infusions following previous intra-arterial therapy and in therapy-naïve territories, respectively (P = NS). Early stasis occurred in 15 of 41 (36.6%) left, 10 of 65 (15.4%) right and one of 22 (4.5%) whole liver infusions (P < 0.001). Rates of partial response and stable disease were similar in the stasis (88.3%) and non-stasis (76.0%) groups (P = NS).
Conclusions: Early stasis occurred in approximately 20% of infusions with similar incidences in hyper- and hypovascular tumours. Whole-liver therapy reduced the incidence of stasis. Stasis did not appear to affect initial imaging outcomes.
© 2013 International Hepato-Pancreato-Biliary Association.
Figures
Similar articles
-
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007. J Vasc Interv Radiol. 2014. PMID: 24461133
-
90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.J Comp Eff Res. 2013 Jul;2(4):435-44. doi: 10.2217/cer.13.37. J Comp Eff Res. 2013. PMID: 24236684 Review.
-
Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.J Vasc Interv Radiol. 2012 Oct;23(10):1294-301. doi: 10.1016/j.jvir.2012.07.009. Epub 2012 Aug 24. J Vasc Interv Radiol. 2012. PMID: 22922039
-
Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.J Vasc Interv Radiol. 2012 May;23(5):669-74. doi: 10.1016/j.jvir.2012.01.059. J Vasc Interv Radiol. 2012. PMID: 22525023 Review.
-
Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization.J Vasc Interv Radiol. 2010 Sep;21(9):1385-95. doi: 10.1016/j.jvir.2010.04.030. Epub 2010 Aug 4. J Vasc Interv Radiol. 2010. PMID: 20688531
Cited by
-
Transarterial Radioembolization: Overview of Radioembolic Devices.Semin Intervent Radiol. 2023 Nov 2;40(5):461-466. doi: 10.1055/s-0043-1772814. eCollection 2023 Oct. Semin Intervent Radiol. 2023. PMID: 37927522 Review. No abstract available.
-
Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma.Indian J Radiol Imaging. 2022 Sep 19;32(4):540-554. doi: 10.1055/s-0042-1754361. eCollection 2022 Dec. Indian J Radiol Imaging. 2022. PMID: 36451961 Free PMC article. Review.
-
Current Approach to Planning Angiography and MAA Administration.Semin Intervent Radiol. 2021 Oct;38(4):397-404. doi: 10.1055/s-0041-1735616. Epub 2021 Oct 7. Semin Intervent Radiol. 2021. PMID: 34629705 Free PMC article. Review.
-
Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.Nucl Med Mol Imaging. 2021 Aug;55(4):162-172. doi: 10.1007/s13139-021-00709-3. Epub 2021 Jul 13. Nucl Med Mol Imaging. 2021. PMID: 34422126 Free PMC article. Review.
-
Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.Molecules. 2021 Jun 29;26(13):3966. doi: 10.3390/molecules26133966. Molecules. 2021. PMID: 34209590 Free PMC article. Review.
References
-
- Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology. 2010;138:52–64. - PubMed
-
- Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomized trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711–1720. - PubMed
-
- Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–529. - PubMed
-
- Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–945. - PubMed
-
- Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18:553–561. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous